Conatus Pharmaceuticals Inc. [NASDAQ:CNAT]: Analyst Rating and Earnings
Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to Conatus Pharmaceuticals Inc. [CNAT] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give CNAT an Hold rating. Its stock price has been found in the range of 1.08 to 6.74. This is compared to its latest closing price of $1.16.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Conatus Pharmaceuticals Inc. [CNAT] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 2.00.
For the quarter ending in Dec-18 Conatus Pharmaceuticals Inc. [CNAT] generated $0.01 billion in sales. That’s 14.14% lower than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Wed 1 May (In 29 Days).
Fundamental Analysis of Conatus Pharmaceuticals Inc. [CNAT]
Now let’s turn to look at profitability: with a current Operating Margin for Conatus Pharmaceuticals Inc. [CNAT] sitting at -54.42, this company’s Net Margin is now -53.60%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -53.32, and its Return on Invested Capital has reached -66.70%. Its Return on Equity is -65.02, and its Return on Assets is -27.55. These metrics suggest that this Conatus Pharmaceuticals Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is 0.27. The Enterprise Value to Sales for this firm is now -0.15. Conatus Pharmaceuticals Inc. [CNAT] has a Price to Book Ratio of 2.09.
Shifting the focus to workforce efficiency, Conatus Pharmaceuticals Inc. [CNAT] earns $1,083,419 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 9.54 and its Total Asset Turnover is 0.51. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.56 and its Current Ratio is 2.56. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Conatus Pharmaceuticals Inc. [CNAT] has 34.07M shares outstanding, amounting to a total market cap of $46.34M. Its stock price has been found in the range of 1.08 to 6.74. At its current price, it has moved by -79.81% from its 52-week high, and it has moved 25.93% from its 52-week low.
This stock’s Beta value is currently 3.34, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 37.19. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Conatus Pharmaceuticals Inc. [CNAT] a Reliable Buy?
Conatus Pharmaceuticals Inc. [CNAT] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.